Loading...
Generating destination analysis
Catalyst Play
Featured in “Three Gene-Editing Stocks to Own Before Biotech's Fall 2026 Catalyst Wave”
Fall '26 Readouts
Recursion Pharmaceuticals uses AI to discover drugs at a fraction of the usual cost and time, with multiple programs reading out. A risk-on biotech tape rewards the platform with the most shots on goal — and Recursion has more than almost anyone in the space.
The catalyst: The back half of 2026 is one of the most catalyst-dense stretches biotech has seen in years. The ESMO oncology congress and the ASH hematology meeting both land in the autumn, and the FDA's decision calendar is stacked — including a closely watched November 14 PDUFA date for ivonescimab in lung cancer. Clusters like this drive sector-wide risk-on, and capital flows first to the platforms with the deepest pipelines and clearest readouts. These three sit at the center of genetic medicine.
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Key Numbers
Market Cap
$4B
P/E
N/A
Revenue Growth
+55.0%
Gross Margin
N/A
ROE
N/A
About Recursion Pharmaceuticals
Listed on the NASDAQ, Recursion Pharmaceuticals operates as a small-cap player in the biotech sector, offering investors focused access to biotech and genomics growth drivers. AI-driven drug discovery platform using machine learning to decode biology at scale. With a $4B market capitalization and no current profitability, the business is characterized by exceptional revenue growth, reporting +55% revenue change year-over-year.
Expert Coverage
Unlock Full RXRX Analysis
Expert analysis and coverage for Recursion Pharmaceuticals
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-06-22
More in Biotech & Genomics
BEAM
Beam Therapeutics
90
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3BDXCM
DexCom Inc.
90
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55ALNY
Alnylam Pharmaceuticals
90
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%CRSP
CRISPR Therapeutics
86
True North
Pure Play
Pioneer of CRISPR gene-editing therapy with first approved treatment for sickle cell disease.
NASDAQ
MCap $5BRev +350%